GlassScriptPhysician profile
Peggy Stouffer
NPI 1841432119
$7,980.86
in general payments reported to CMS, 2019-2025
42 companies · $942 in 2025
The $942 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,723 · 2022: $2,337 · 2023: $1,698 · 2024: $1,281 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,907.14 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,031.81 | 2021-2025 | |
| Astellas Pharma US INC | $668.24 | 2021-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $524.05 | 2021-2025 | Slynd |
| Pfizer INC. | $508.72 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $430.99 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $323.90 | 2021-2025 | |
| Therapeuticsmd, INC. | $265.91 | 2021-2022 | |
| Daiichi Sankyo INC. | $259.37 | 2021-2025 | Injectafer |
| Coopersurgical, INC. | $236.16 | 2021-2025 | Paragard T 380a, Paragard T 380a, Mara Console |
| Evofem Biosciences, INC. | $228.22 | 2021-2024 | Phexxi |
| Scynexis, INC. | $222.60 | 2022 | |
| Myovant Sciences INC. | $211.63 | 2021-2022 | |
| Bausch Health US, LLC | $205.82 | 2021-2024 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $181.77 | 2021-2024 | Trintellix |
| Organon LLC | $171.35 | 2022-2024 | Nexplanon |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peggy Stouffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.